In parallel with this cause-effect finding in the mouse model, we observed that wild-type RRAS2 is overexpressed in more than 50% of breast cancer samples, including luminal A, luminal B, HER2-enriched, and TNBC subtypes, with the highest frequency (75%) and expression levels found in TNBC. Here, ERBB2 is linked to breast carcinoma.